Toho Pharmaceutical To Buy Back 2 Million Shares
This article was originally published in PharmAsia News
Executive SummaryJapanese drug wholesaler Tokyo based Toho Pharmaceutical Feb. 13 offered to buy back 2 million shares, which account for 3.29 percent of the company's total outstanding shares. Toho plans to pay up to ¥2.5 billion for the shares. The buyback period is Feb. 16 to March 24. Since Feb. 4, when the company lowered its estimated sales for the full year, share prices plunged to ¥750, a five year low. (Click here for more - Japanese language
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.